NanoViricides Corp - NNVC Forward P/S Multiple

nanoviricides.com (NNVC) - corporate logo

NanoViricides, Inc. (NNVC) is integrating ESG principles into the development of nanotechnological antiviral agents while strictly adhering to bioethics. The company's modeled P/S ratio confirms the valuation trend, where reflects the metric's baseline level. Returns are based on the development of innovative nanomedicines that block pathogen particles. Complex chemical patents for polymers create an insurmountable barrier to the replication of technologies by third-party laboratories.

NNVC NanoViricides Inc.: Market Cap to Projected Revenue in the range 07/04/2022 - 11/13/2026

nanoviricides.com (NNVC) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart NanoViricides|NNVC - Broker Consensus Forecast
- issuer market value details:
Market Capitalization NanoViricides, Inc.|NNVC - Enterprise Value
- issuer book value statistics:
Net Assets per Single Share NanoViricides|NNVC - Accounting Capitalization|Market Value to Book Value Ratio nanoviricides.com|NNVC - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio NanoViricides, Inc.|NNVC - Long-Term Debt to Equity|Short-Term Debt to Capital NanoViricides|NNVC - Company Total Debt Obligations|Debt to Book Capitalization Ratio NanoViricides, Inc.|NNVC - Company Long-Term Loans and Borrowings|Company Short-Term Debts NanoViricides|Quick Ratio nanoviricides.com
- business earnings and investment ratios data:
NNVC - Net Income|Projected Future Earnings NanoViricides, Inc.|NNVC - Business Payback Period|Forward P/E Multiple NanoViricides|NNVC - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple NanoViricides, Inc.|NNVC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months NanoViricides|NNVC - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months nanoviricides.com|NNVC - Earnings per share increase in current year|Earnings growth forecast for next year NanoViricides, Inc.
- sales and revenue indicators:
NNVC - Company Gross Revenue|Company Projected Revenue NanoViricides|NNVC - Market Cap to Revenue Ratio|Forward P/S Multiple NanoViricides, Inc.
Comprehensive company analysis:NNVC (NanoViricides Corp)
Manufactured products of nanoviricides.com

For NanoViricides, Inc. (NNVC), whose prospects are driven by exclusive patents and FDA rulings, assessing market value relative to expected revenues is critical. The forward P/S ratio compares current market capitalization with projected revenue for the coming year, allowing investors to gauge the level of optimism currently priced in and the risk of a correction should clinical milestones not be met.

Key competitors

Price-to-Projected Revenue Ratio Gilead Sciences GILD|CDTX: Market Cap to Projected Revenue|Novavax Corp - Forward P/S Multiple|CVAC - Forward P/S Multiple|Valneva SE (VALN) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue VIR|Price-to-Projected Revenue Ratio SIGA Technologies|Market Cap to Future Revenue Ratio Emergent BioSolutions Inc EBS|Forward Price-to-Revenue Multiple AVIR (Atea Pharmaceuticals Inc)|Price-to-Projected Revenue Ratio IVVD (invivyd.com)|Forward P/S Multiple ENTA (Enanta Pharmaceuticals)|Market Cap to Expected Sales Ratio inovio.com (INO)|HLVX - Price-to-Projected Revenue Ratio|Forward Price to Sales KLRS (Kalaris Therapeutics Inc.)|DYAI: Forward P/S Multiple|TLPH - Market Cap to Expected Sales Ratio|COCP (Cocrystal Pharma, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Traws Therapeutics (TRAW)|Forward P/S Multiple DWTX|Market Cap to Expected Sales Ratio Qualigen Therapeutics Inc|Forward P/S Multiple ALVR (AlloVir)|VBIV: Market Cap to Projected Revenue|Virios - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vaxart, Inc.